




RealRate

# PHARMACEUTICAL 2023

## Sarepta Therapeutics Inc. Rank 302 of 446





RealRate

# PHARMACEUTICAL 2023

## Sarepta Therapeutics Inc. Rank 302 of 446



The relative strengths and weaknesses of Sarepta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sarepta Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 41% points. The greatest weakness of Sarepta Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is -1.4%, being 45% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,557,861
Cost of Goods Sold	0
Intangible Assets	7,578
Liabilities, Current	619,604
Liabilities, Non-Current	542,620
Other Assets	382,890
Other Compr. Net Income	-1,644
Other Expenses	154,228
Other Liabilities	1,581,192
Other Net Income	-153,762
Other Revenues	933,013
Property and Equipment	180,037
Research and Development	877,090
Selling, General and Administrative Expense	451,421

Output Variable	Value in 1000 USD
Assets	3,128,366
Liabilities	2,743,416
Expenses	1,482,739
Revenues	933,013
Stockholders Equity	384,950
Net Income	-703,488
Comprehensive Net Income	-704,310
Economic Capital Ratio	-1.4%